ランキングに戻る

Henry Schein, Inc. (HSIC)

適正価値
HealthcareMedical DistributionUnited States

ファンダメンタル

58

株価

$84.82

時価総額

$9.57B

パート1 · 企業の価値

概要

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users

P/E: 24.1Score: 78Market cap: $99.84B

Cited by Henry Schein as one of two national competitors in medical distribution, McKesson supplies the same office-based physicians and alternate-care sites with pharmaceuticals and medical-surgical products.

P/E: 33.1Score: 76Market cap: $51.78B

Its Medical segment distributes surgical and examination supplies to physician offices, ambulatory surgery centers and home-care providers, the same alternate-care customers Henry Schein Medical serves.

Patterson Companies, Inc. (Patterson Dental)Not tracked

Named in Henry Schein's 10-K as its main U.S. rival, Patterson Dental sells the same consumables, equipment and practice-management software to the same dental offices, and has been privately held since Patient Square Capital took it off Nasdaq in April 2025.

Benco Dental Supply CompanyNot tracked

The third full-service dental distributor in the United States, family-owned and unlisted, competing with Henry Schein practice by practice for the same dental supply and equipment budgets.

Medline Industries, LPNot tracked

The other national medical competitor named in the 10-K, privately held, selling medical-surgical supplies to the same physician practices, surgery centers and long-term care facilities.

貸借対照表と流動性

売上高

$13.60B

直近12か月(2026/6/27まで)

純利益

$403M

直近12か月(2026/6/27まで)

フリーキャッシュフロー

$573M

自己資本合計

$3.25B

負債合計

$6.42B

流動比率

1.32

利払い倍率

4.28

負債/EBITDA

3.96

一株当たり利益(EPS)

売上高と純利益

フリーキャッシュフロー

収益内訳

財務推移表

利益率の推移

負債の推移

負債の重さ

成長率グリッド

成長率 — 売上高

適正価値の推定

一般的なケース適正価値

適正価値

$77.47

現在株価

$84.82

安全マージン

-9.5%

適正価値レンジ

$53.98 - $100.95

使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。

推定方法

アナリストの目標株価:$97.27
ディスカウンテッド・キャッシュフロー(DCF):$97.21
利益倍率(P/E):$51.61
グレアムの成長公式:$43.59
収益力価値(EPV):$50.50
正当化されたP/B:$40.68
配当割引モデル(ゴードン):算出に必要なデータが不足しています
P/FFO(運用から生まれる資金):$101.79
中間サイクル利益:$163.35
売上高倍率:$466.69
アナリスト・コンセンサス:買い (15B / 9H / 1S)
直近の決算サプライズ:+0.67%

バリュエーション指標

P/E レシオ

24.76

ROE

12.3%

P/B レシオ

3.00

P/FCF

16.63

粗利益率

31.3%

ROIC

6.8%

収益性レーダー

価値創造(経済的モート)

ROIC

6.8%

WACC

7.5%

ROIC − WACC

-0.7 pp

ROICはおおむね資本コストと同水準です。企業はかろうじて資本コストを賄えている状態です。

ファンダメンタル分析基準

合格(18)

  • EPS shows upward trend
  • ROIC 6.8%
  • Gross Margin 31.3%
  • P/FCF 16.63
  • P/B Ratio 3.00
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 12.4%
  • Revenue Growth 5Y 5.4%
  • Analyst Consensus 60% Buy
  • Earnings Surprise avg 3.5%
  • Earnings Quality (OCF/NI) 1.74
  • Share Dilution -4.8%

不合格(9)

  • EPS CAGR 1.29%
  • Price CAGR 3.64%
  • Operating Margin 5.0%
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • PEG Ratio 7.91
  • Net Margin Trend 3.0% vs 3.0%
  • Piotroski F-Score 4/9

データなし(1)

  • Dividend Payout NaN%

Piotroski F-スコア

4/9

まちまちのシグナル:一部の領域に注意が必要

score
criteria

利益の質

1.74

高品質:利益はキャッシュに裏付けられている

株式希薄化

-4.8%

株式を買い戻している。株主に友好的

機関投資家の保有

ガバナンス

経営陣

氏名役職年齢
Mr. Ronald N. SouthSenior VP & CFO63
Mr. Michael Saul EttingerExecutive VP & COO64
Mr. Mark E. MlotekExecutive VP & Chief Strategic Officer69
Mr. Andrea AlbertiniChief Executive Officer of Global Distribution & Technology55
Mr. Frederick M. LoweryCEO & Director54
Ms. Olga TimoshkinaVP of Corporate Finance & Chief Accounting Officer-
Mr. Christopher PendergastSenior VP & CTO62
Mr. Graham StanleyVP of Investor Relations & Strategic Finance Project Officer-
Ms. Kelly Murphy J.D.Senior VP & General Counsel44
Ms. Christine SheehySenior VP & Chief Human Resources Officer57

監査リスク

4

取締役会リスク

8

報酬リスク

6

株主権利リスク

4

パート2 · 株価と買い時

この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。

書類

  • 年次報告書(10-K)

    事業内容、財務実績、リスクをまとめた年次の概要。

    提出日: 2026-02-24

    書類を見る
  • 四半期報告書(10-Q)

    直近3か月間の業績に関する最新情報。

    提出日: 2026-08-04

    書類を見る
  • 臨時報告書(8-K)

    経営陣の交代や重要な発表など、大きな出来事に関するお知らせ。

    提出日: 2026-09-22

    書類を見る

via SEC EDGAR

業績推移

via SEC EDGAR

Latest News

Recent headlines for HSIC, sourced from Markets Gazette.

  • 6/11/2026POSITIVE
    This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

    Henry Schein Inc. (HSIC) has received a bullish upgrade from Wall Street analysts, signaling a potentially positive outlook for the company's stock. While specific details of the upgrade and the analysts' reasoning are not provided in this snippet, such a shift in sentiment typically suggests that analysts foresee improved financial performance, strategic advantages, or favorable market conditions for HSIC. Investors often view analyst upgrades as a catalyst for stock price appreciation, potentially leading to increased buying interest and upward price momentum.

  • 2/24/2026NEUTRAL
    Henry Schein (HSIC) Q4 2025 Earnings Transcript

    Investors in Henry Schein Inc. (HSIC) are poised to analyze the Q4 2025 earnings transcript, released on February 24, 2026. This event is pivotal for understanding the financial performance of the company, a global leader in distributing healthcare products and services to medical and dental practices. The report's analysis will provide crucial details on revenues, earnings per share (EPS), operating margins, and future outlook, which are fundamental elements for assessing the company's health and potential growth trajectories. While specific data is not yet available for direct evaluation, the transcript's release marks a key moment for the market, allowing deeper insight into management's statements and responses to analyst questions, thereby shaping expectations for the upcoming fiscal period and its impact on share value.

via Markets Gazette